• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

First participant with Down syndrome joins Alzheimer’s prevention trial

April 11, 2025
in Medical Research
Reading Time: 5 mins read
A A
0
Down syndrome
5
SHARES
10
VIEWS
Share on FacebookShare on Twitter


Down syndrome
Credit: Cliff Booth from Pexels

Researchers have dosed the first participant in a clinical trial of an investigational medicine designed to lower the amount of amyloid precursor protein (APP) for the potential treatment of Alzheimer’s disease (AD), which is initially being studied in adults with Down syndrome (DS) who have a genetic risk of developing AD.

The focus on prevention represents a significant shift towards attacking Alzheimer’s disease earlier in its progression, rather than at the treatment stage. Those with Down syndrome are born with an extra chromosome that carries a gene pivotal to causing Alzheimer’s. The gene produces a protein that causes a buildup of plaques in the brain.

By the time most people with Down syndrome hit age 40, they have already developed these plaques. It may take another decade or more to develop symptoms, but eventually up to nine in 10 people with Down syndrome are expected to develop Alzheimer’s disease.

Seeking to change these odds, last month, researchers gave the first dose of an investigative drug to a participant in the new clinical trial, called the HERO study. The drug is designed to stop Alzheimer’s-causing plaques from forming in the brain.

Led by Ionis Pharmaceuticals, with investigative oversight by ATRI Medical Director Michael Rafii, MD, Ph.D., the study is expected to run for two years with an initial 30 participants at sites across the U.S. and Europe.

“What makes this study remarkable is that it targets the underlying genetic cause of Alzheimer’s disease in people with Down syndrome,” said Rafii.

Accelerating the pace of research into Alzheimer’s disease in the Down syndrome population

Though research first linked Alzheimer’s disease to those with Down syndrome more than 30 years ago, few clinical trials have been done for this group—until now. With this new effort, Rafii noted the growing number of clinical trials specifically designed for people with Down syndrome, including one called the ABATE study, launched last year.

Rafii is the coordinating principal investigator for ABATE, which is evaluating a vaccine intended to slow down Alzheimer’s in those with Down syndrome by targeting amyloid plaques in the brain.

Later in 2025, Rafii and the ATRI team will initiate the ALADDIN trial, which will investigate the use of donanemab in people with Down syndrome. Donanemab is already FDA-approved for Alzheimer’s in the general population.

“Now someone with Down syndrome can go into one of these specialized research clinics and select from several trials,” Rafii said. “That’s never been the case in this field. Ever.”

These trials represent just a slice of the recent progress made in Down syndrome research, described in a new Lancet article co-authored by Rafii and USC Associate Professor of Clinical Neurology and Pediatrics Jonathan D. Santoro, MD.

The HERO study is working closely with the Alzheimer’s Clinical Trials Consortium—Down Syndrome (ACTC-DS), a large, international consortium led by Rafii. ACTC-DS conducts research and clinical trials with a focus on advancing Alzheimer’s disease therapies for those with Down syndrome.

It also works closely with the Alzheimer’s Biomarker Consortium—Down Syndrome (ABC-DS), an observational study that has provided critical scientific information about how and when Alzheimer’s develops in people with Down syndrome.

ACTC-DS collaborates with advocacy groups such as the National Down Syndrome Society and the Global Down Syndrome Foundation to raise awareness about the genetic connection between Down syndrome and Alzheimer’s disease and incorporate input from an advisory group of individuals with Down syndrome and their loved ones. This feedback helps to ensure that the voices and needs of those with Down syndrome are prioritized in research.

The first project of the ACTC—DS created a cohort of 120 people with Down syndrome who could be ready to participate in clinical trials. The project exceeded its goal, enrolling over 350 people. This was particularly important, because too often those with Down syndrome do not receive adequate access to health care and are ineligible for clinical trials. Having interested participants already identified speeds up the pace of research.

How is this new investigational drug designed to work?

The new investigative drug being evaluated in this study, ION269, is designed to interrupt the production of amyloid plaques. ION269 is part of a class of medicines called antisense oligonucleotides.

Participants in the HERO study will receive an injection of the investigational drug into the lower back. The medicine will then travel to the brain where it is intended to work. The goal of the study is to assess safety and tolerability and the effects of this treatment on APP and amyloid plaques in the brain.

Before enrolling any participant, researchers secure the consent of both the candidate being considered and their legally authorized representatives. The consent materials are designed specifically for those with intellectual disabilities and have been reviewed by the ACTC-DS advisory group.

Researchers are seeking participants to take part in the HERO study, which began at Washington University School of Medicine in St. Louis. The University of Kansas Medical Center is another active study site. Many more research sites are expected to come on board in the coming months.

More information:
Jonathan D Santoro et al, Reflecting on progress, envisioning the future for research in Down syndrome, The Lancet (2025). DOI: 10.1016/S0140-6736(25)00510-0

For more information or to get involved, visit the HERO study website or ClinicalTrials.gov.

Provided by
Keck School of Medicine of USC


Citation:
First participant with Down syndrome joins Alzheimer’s prevention trial (2025, April 11)
retrieved 11 April 2025
from https://medicalxpress.com/news/2025-04-syndrome-alzheimer-trial.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Down syndrome
Credit: Cliff Booth from Pexels

Researchers have dosed the first participant in a clinical trial of an investigational medicine designed to lower the amount of amyloid precursor protein (APP) for the potential treatment of Alzheimer’s disease (AD), which is initially being studied in adults with Down syndrome (DS) who have a genetic risk of developing AD.

The focus on prevention represents a significant shift towards attacking Alzheimer’s disease earlier in its progression, rather than at the treatment stage. Those with Down syndrome are born with an extra chromosome that carries a gene pivotal to causing Alzheimer’s. The gene produces a protein that causes a buildup of plaques in the brain.

By the time most people with Down syndrome hit age 40, they have already developed these plaques. It may take another decade or more to develop symptoms, but eventually up to nine in 10 people with Down syndrome are expected to develop Alzheimer’s disease.

Seeking to change these odds, last month, researchers gave the first dose of an investigative drug to a participant in the new clinical trial, called the HERO study. The drug is designed to stop Alzheimer’s-causing plaques from forming in the brain.

Led by Ionis Pharmaceuticals, with investigative oversight by ATRI Medical Director Michael Rafii, MD, Ph.D., the study is expected to run for two years with an initial 30 participants at sites across the U.S. and Europe.

“What makes this study remarkable is that it targets the underlying genetic cause of Alzheimer’s disease in people with Down syndrome,” said Rafii.

Accelerating the pace of research into Alzheimer’s disease in the Down syndrome population

Though research first linked Alzheimer’s disease to those with Down syndrome more than 30 years ago, few clinical trials have been done for this group—until now. With this new effort, Rafii noted the growing number of clinical trials specifically designed for people with Down syndrome, including one called the ABATE study, launched last year.

Rafii is the coordinating principal investigator for ABATE, which is evaluating a vaccine intended to slow down Alzheimer’s in those with Down syndrome by targeting amyloid plaques in the brain.

Later in 2025, Rafii and the ATRI team will initiate the ALADDIN trial, which will investigate the use of donanemab in people with Down syndrome. Donanemab is already FDA-approved for Alzheimer’s in the general population.

“Now someone with Down syndrome can go into one of these specialized research clinics and select from several trials,” Rafii said. “That’s never been the case in this field. Ever.”

These trials represent just a slice of the recent progress made in Down syndrome research, described in a new Lancet article co-authored by Rafii and USC Associate Professor of Clinical Neurology and Pediatrics Jonathan D. Santoro, MD.

The HERO study is working closely with the Alzheimer’s Clinical Trials Consortium—Down Syndrome (ACTC-DS), a large, international consortium led by Rafii. ACTC-DS conducts research and clinical trials with a focus on advancing Alzheimer’s disease therapies for those with Down syndrome.

It also works closely with the Alzheimer’s Biomarker Consortium—Down Syndrome (ABC-DS), an observational study that has provided critical scientific information about how and when Alzheimer’s develops in people with Down syndrome.

ACTC-DS collaborates with advocacy groups such as the National Down Syndrome Society and the Global Down Syndrome Foundation to raise awareness about the genetic connection between Down syndrome and Alzheimer’s disease and incorporate input from an advisory group of individuals with Down syndrome and their loved ones. This feedback helps to ensure that the voices and needs of those with Down syndrome are prioritized in research.

The first project of the ACTC—DS created a cohort of 120 people with Down syndrome who could be ready to participate in clinical trials. The project exceeded its goal, enrolling over 350 people. This was particularly important, because too often those with Down syndrome do not receive adequate access to health care and are ineligible for clinical trials. Having interested participants already identified speeds up the pace of research.

How is this new investigational drug designed to work?

The new investigative drug being evaluated in this study, ION269, is designed to interrupt the production of amyloid plaques. ION269 is part of a class of medicines called antisense oligonucleotides.

Participants in the HERO study will receive an injection of the investigational drug into the lower back. The medicine will then travel to the brain where it is intended to work. The goal of the study is to assess safety and tolerability and the effects of this treatment on APP and amyloid plaques in the brain.

Before enrolling any participant, researchers secure the consent of both the candidate being considered and their legally authorized representatives. The consent materials are designed specifically for those with intellectual disabilities and have been reviewed by the ACTC-DS advisory group.

Researchers are seeking participants to take part in the HERO study, which began at Washington University School of Medicine in St. Louis. The University of Kansas Medical Center is another active study site. Many more research sites are expected to come on board in the coming months.

More information:
Jonathan D Santoro et al, Reflecting on progress, envisioning the future for research in Down syndrome, The Lancet (2025). DOI: 10.1016/S0140-6736(25)00510-0

For more information or to get involved, visit the HERO study website or ClinicalTrials.gov.

Provided by
Keck School of Medicine of USC


Citation:
First participant with Down syndrome joins Alzheimer’s prevention trial (2025, April 11)
retrieved 11 April 2025
from https://medicalxpress.com/news/2025-04-syndrome-alzheimer-trial.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Schools lined up for help getting cleaner school buses. Then came the EPA freeze

Next Post

‘We made a mistake’: REI apologizes for supporting Trump public lands pick

Related Posts

baby

Brain connections at 3 months predict infant emotional development

June 3, 2025
4

Influencer Urges Parents to Give Kids Bleach to Treat Autism Despite Reports of Vomiting, Suffering Seizures: Report

June 3, 2025
6
Next Post
‘We made a mistake’: REI apologizes for supporting Trump public lands pick

‘We made a mistake’: REI apologizes for supporting Trump public lands pick

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
China passenger trips up 3% during Dragon Boat holiday

China passenger trips up 3% during Dragon Boat holiday todayheadline

June 3, 2025
ET logo

Who is Alex Marquardt, and how a defamation case cost CNN nearly $5 million todayheadline

June 3, 2025
artist image of young star system

Water Discovered Around a Young, Sun-Like Star For First Time : ScienceAlert todayheadline

June 3, 2025
Ptolemaeus, Alphonsus, and Arzachel

The Sky Today on Tuesday, June 3: A trio of craters

June 3, 2025

Recent News

China passenger trips up 3% during Dragon Boat holiday

China passenger trips up 3% during Dragon Boat holiday todayheadline

June 3, 2025
4
ET logo

Who is Alex Marquardt, and how a defamation case cost CNN nearly $5 million todayheadline

June 3, 2025
3
artist image of young star system

Water Discovered Around a Young, Sun-Like Star For First Time : ScienceAlert todayheadline

June 3, 2025
4
Ptolemaeus, Alphonsus, and Arzachel

The Sky Today on Tuesday, June 3: A trio of craters

June 3, 2025
3

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

China passenger trips up 3% during Dragon Boat holiday

China passenger trips up 3% during Dragon Boat holiday todayheadline

June 3, 2025
ET logo

Who is Alex Marquardt, and how a defamation case cost CNN nearly $5 million todayheadline

June 3, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co